QuantuMDx Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
71
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$9.9M
- Investors
-
11
QuantuMDx General Information
Description
Developer of a point-of-care molecular diagnostic system designed to provide rapid, multiplexed testing for infectious diseases. The company's device uses sophisticated software algorithms and PCR technology to deliver clear results for sexually transmitted infections, respiratory viruses, and antimicrobial resistance, enabling healthcare providers to make targeted treatment decisions at the point of care.
Contact Information
Website
www.quantumdx.comCorporate Office
- Lugano Building
- 57 Melbourne Street
- Newcastle Upon Tyne NE1 2JQ
- England, United Kingdom
Corporate Office
- Lugano Building
- 57 Melbourne Street
- Newcastle Upon Tyne NE1 2JQ
- England, United Kingdom
QuantuMDx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 23-Nov-2022 | $9.9M | Completed | Generating Revenue | ||
| 10. Later Stage VC | 21-Oct-2021 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 27-Jan-2020 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 25-Jan-2019 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 01-Dec-2017 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 14-Dec-2016 | Completed | Startup | |||
| 5. Later Stage VC | 22-Dec-2015 | Completed | Startup | |||
| 4. Angel (individual) | 08-Dec-2014 | Completed | Startup | |||
| 3. Product Crowdfunding | 12-Feb-2014 | $18.1K | Completed | Startup | ||
| 2. Grant | 17-Oct-2013 | $1.6M | Completed | Startup |
QuantuMDx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 16,026 | $0.011620 | $339.8 | $339.8 | 1x | $339.8 | 3.7% | |
| Ordinary | 35,821 | $0.011620 | $280.44 | $280.44 | 1x | $280.44 | 8.27% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
QuantuMDx Comparisons
Industry
Financing
Details
QuantuMDx Competitors (29)
One of QuantuMDx’s 29 competitors is Abionic, a Venture Capital-Backed company based in Lausanne, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abionic | Venture Capital-Backed | Lausanne, Switzerland | ||||
| Q-linea | Formerly VC-backed | Uppsala, Sweden | ||||
| Vela Diagnostics | Corporate Backed or Acquired | Singapore, Singapore | ||||
| BioFire | Venture Capital-Backed | Salt Lake City, UT | ||||
| Biocartis | Venture Capital-Backed | Mechelen, Belgium |
QuantuMDx Patents
QuantuMDx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026229144-A1 | Droplet collector and microfluidic devices containing the same | Pending | 28-Apr-2025 | ||
| GB-202506398-D0 | Droplet collector and miucrofluidic devices containing the same | Pending | 28-Apr-2025 | ||
| EP-4808691-A1 | Flow regulators for the control of liquid fronts in microfluidic structures | Pending | 16-Nov-2023 | ||
| GB-2636565-A | Flow regulators for the control of liquid fronts in microfluidic structures | Active | 16-Nov-2023 | ||
| GB-2636565-B | Flow regulators for the control of liquid fronts in microfluidic structures | Active | 16-Nov-2023 | B01L3/50273 |
QuantuMDx Signals
QuantuMDx Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Astrid Hill Investment | Venture Capital | Minority | ||
| British Business Bank | Lender/Debt Provider | Minority | ||
| Vita Spring IVD Fund | Venture Capital | Minority | ||
| Adjuvo | Venture Capital | Minority | ||
| 3B Future Health Fund | Venture Capital | Minority |
QuantuMDx Acquisitions (1)
QuantuMDx’s most recent deal was a Merger/Acquisition with Northgene. The deal was made on 01-Mar-2013.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Northgene | 01-Mar-2013 | Merger/Acquisition | Laboratory Services (Healthcare) |
QuantuMDx Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Northgene | Deeside, United Kingdom | 1994 |
QuantuMDx FAQs
-
When was QuantuMDx founded?
QuantuMDx was founded in 2008.
-
Where is QuantuMDx headquartered?
QuantuMDx is headquartered in Newcastle Upon Tyne, United Kingdom.
-
What is the size of QuantuMDx?
QuantuMDx has 71 total employees.
-
What industry is QuantuMDx in?
QuantuMDx’s primary industry is Diagnostic Equipment.
-
Is QuantuMDx a private or public company?
QuantuMDx is a Private company.
-
What is the current valuation of QuantuMDx?
The current valuation of QuantuMDx is .
-
What is QuantuMDx’s current revenue?
The current revenue for QuantuMDx is .
-
How much funding has QuantuMDx raised over time?
QuantuMDx has raised $112M.
-
Who are QuantuMDx’s investors?
Astrid Hill Investment, British Business Bank, Vita Spring IVD Fund, Adjuvo, and 3B Future Health Fund are 5 of 11 investors who have invested in QuantuMDx.
-
Who are QuantuMDx’s competitors?
Abionic, Q-linea, Vela Diagnostics, BioFire, and Biocartis are some of the 29 competitors of QuantuMDx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process